Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Details on Person ipragliflozin [extracellular region]

Class:Id	ChemicalDrug:9728119
_displayName	ipragliflozin [extracellular region]
_timestamp	2021-04-21 10:11:47
compartment	[Compartment:984] extracellular region
created	[InstanceEdit:9728224] Jassal, Bijay, 2021-04-20
disease	[Disease:5669063] type 2 diabetes mellitus
literatureReference	[LiteratureReference:9728148] Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo [LiteratureReference:9728506] Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus
modified	[InstanceEdit:9728508] Jassal, Bijay, 2021-04-21
name	ipragliflozin ASP-1941 ASP1941 Suglat®
referenceEntity	[ReferenceTherapeutic:9728177] ipragliflozin [Guide to Pharmacology:9394]
stableIdentifier	[StableIdentifier:9728237] R-ALL-9728119.1
(hasMember)	[DefinedSet:9728134] gliflozins [extracellular region]
[Change default viewing format]

No pathways have been reviewed or authored by ipragliflozin [extracellular region] (9728119)